Relevant concomitant care permitted or prohibited during the trial {11d}
CYP3A4-BDQ, epileptic seizures
EPILEPTIC SEIZURE
BDQ, DLM and MXF are metabolized by different hepatic enzymes (CYP3A4-BDQ and DLM; UDP-glucuronoyltransferase-MXF). A change in activity of these hepatic enzymes can change the drug concentrations in blood and tissue and thereby influence safety and efficacy readouts. Therefore, all drugs that would lead to a substantial change in activity of these enzymes are prohibited. Participants who are already enrolled and on study medication, and a need arises to treat with any of those drugs during the treatment phase of the trial, experimental treatment may have to be stopped.In addition, several other classes of drugs are prohibited during the trial as they might interfere with the assessment of possible AEs of the drugs given during the trial. These drugs include drugs acting on the MTB complex, drugs that might induce epileptic seizures by lowering the threshold, drugs potentially prolonging the QT-interval, drugs affecting the MAO, serotonin agonists and CYP450 inducer or inhibitor. Also, as oxazolidinones are known to have a weak reversible MAO inhibitory effect in vitro, they can block the metabolization of dietary tyramine and thus might act as pressor enhancers [Additionally, all participants able to conceive/father children will consent to be using two effective methods of contraception, one of which must be a barrier method. These will be explained to the participants in detail. Serum pregnancy tests in all females of childbearing potential will be taken at screening, week 09 and week 18 visit.